Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
TileDB builds a database platform for organizing, cataloging, and analyzing large-scale data across organizations. The product serves science and data teams seeking to extract insights from complex, diverse datasets.
7 investors
Using few-shot learning to design better drug candidates, faster
7 investors
Valink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for therapeutic applications, combining high-throughput discovery, antibody engineering, and medicinal chemistry capabilities.
7 investors
VeriSIM uses machine learning and computational simulation to accelerate drug development, replacing traditional trial-and-error experimentation with computational prediction to improve success rates and reduce animal testing. The company serves pharmaceutical partners and research institutions developing new medicines.
7 investors
Vestaron develops peptide-based insecticides derived from naturally-occurring peptides such as those found in spider venom, produced through fermentation, offering new modes of action for crop protection. Its SPEAR brand products target pests on high-value crops for growers in the agriculture and food industries with reduced impact on pollinators and the environment.
7 investors
Wildtype grows salmon directly from fish cells using cellular agriculture, allowing production of seafood without wild-caught or farmed fish. The company serves restaurants and consumers seeking sustainable seafood with reduced contaminants.
7 investors
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcฮณRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor. Its products are aimed at patients with multiple autoimmune conditions with unmet medical needs.
7 investors
AIRNA develops RNA editing therapeutics aimed at providing functional cures for patients with rare diseases and common conditions. The company works in the genetic medicines and biotech space.
7 investors
Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
6 investors
A pharmaceutical company that develops medicines and vaccines for patients globally.
6 investors
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.
6 investors
Aerska develops RNA interference (RNAi) medicines designed for targeted delivery across the blood-brain barrier to treat, delay, and prevent central nervous system and neurological diseases. The company combines next-generation RNA therapeutics, brain delivery technologies, and biomarker-guided precision medicine to silence disease-causing genes in the brain.
6 investors
Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need. Its product candidates target established biological pathways using organ-restricted approaches to resolve fibro-inflammation and restore organ function.
6 investors
Aizon provides data solutions that help organizations analyze historical information and make informed decisions about future outcomes. The company operates in the data infrastructure and analytics space, serving enterprises across various industries.
6 investors
Altis Biosystems builds RepliGutยฎ, human intestinal tissue models grown from human intestinal stem cells that provide human-relevant preclinical data for drug absorption, metabolism, toxicity, and disease modeling. It serves pharmaceutical and life-science researchers as an alternative to animal studies and Caco-2 cell lines, offering ready-to-use kits and custom studies.
6 investors
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability. The company uses human genetic data and clinical expertise to select drug targets in the obesity treatment landscape.
6 investors
Ancilia is a biotech company using CRISPR to create beneficial bacterial products, such as live biotherapeutics, that carry immunity against the viruses that destroy them. It develops computational and biological platforms to identify, characterize, and counter viruses within the microbiome (the virome).
6 investors
Andes adds naturally occurring beneficial microorganisms to agricultural soils alongside crop seeds such as corn, soybean, canola, and wheat, accelerating the conversion of atmospheric COโ into stable soil inorganic carbon. The company sells carbon dioxide removal at scale and runs a carbon program for farmers, while its mineral build-up also improves soil and plant health.
6 investors
Antiverse is a techbio company that uses machine learning and cell line engineering to design de novo antibody therapeutics against difficult targets such as G-protein coupled receptors and ion channels. It works with pharmaceutical companies and develops its own internal antibody pipeline across multiple indications.
6 investors
Aromyx develops biosensor technology that replicates human olfactory receptors to measure and quantify odors and flavors for product development, quality control, and consumer targeting across food, beverage, sustainability, and health industries.
6 investors
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease. Its pipeline includes a candidate for Type 1 Myotonic Dystrophy (DM1), a form of muscular dystrophy.
6 investors
Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors. The company uses computational and engineering approaches to create cancer medicines.
6 investors
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases. The company focuses on long-acting therapeutic formulations to address endocrine and rare disease indications.
6 investors
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity. The company is advancing etakafusp alfa, a cis-targeting IL-2 candidate, for solid tumor treatment and applying its platform to oncology and infectious disease indications.
6 investors